Session: 801. Gene Therapies: Poster II
Hematology Disease Topics & Pathways:
Research, Fundamental Science, Biological therapies, Gene Therapy, Therapies
Methods: Custom mRNA transcripts modified with N1-methylpseudouridine and packaged into LNPs (diameter 80 ± 5nm; PDI 0.01), their performance was tested ex vivo and in vivo. LNPmRNA were delivered either intrafemorally or by tail vein injection into Fancc-/- mice, a mouse model of FA or Ai14 mice, a Cre-sensitive reporter mouse model. We also tested LNP performance using ex vivo expanded hematopoietic stem and progenitor cell (HSPC) populations and fresh CD150+CD48-Lin-Sca1+ckit+ (long-term hematopoietic stem cells; LT-HSC) cells obtained from wildtype (WT, Fancc+/+) and knockout (KO, Fancc-/-) mice. LNP formulations delivered mRNA transcripts of the fluorescent reporter mCherry (LNPmCherry), cre-recombinase (LNPCre), luciferase bioluminescent reporter gene (LNPLuc) or a truncated murine FANCC gene (LNPFancc).
Results: To characterize access to the bone marrow compartment in vivo, we delivered LNPmCherry or LNPCre via systemic (intravenous) and direct (intraosseous) routes to healthy WT and Ai14 mice. Using LNPCre, we achieve up to 92.6% ± 5% tdTomato reporter expression in Lin-Sca1+ckit+ (LSK) cells 5 days following intraosseous delivery. Consistent with reports by others, we demonstrate lower average transfection rate of 24.8% ± 15.9% fluorescent positivity rates in LSK cells after intraosseous LNPmCherry delivery, and 9.5% ± 6.7% after intravenous delivery. mCherry fluorescent signal was detectable by FACS for up to 72 hours following LNPmCherry injection. We reasoned that meaningful FA HSC correction would require more extended protein expression. Circular mRNA shows improved biostability and durability of expression. Comparing both linear and circular mRNA performance, we observed that circularized LNPLuc is expressed for up to 7 days post ex vivo exposure in LT-HSC populations as compared to 3 days when using linear LNPLuc. Functionally, ex vivo LNPFancc treatment improves proliferation rates and Mitomycin C (MMC) resistance in colony forming unit (CFU) assays of Fancc-/- HSPC. Here, LNPFancc treated HSPC demonstrate improved MMC survival rates reaching 37.2% ± 10.5% up from 16.1% ± 8.2%. Ex vivo expanded Fancc-/- HSPC demonstrate an even greater benefit from LNPFancc treatment, with CFU survival rates increasing to 62.7% from a baseline of 3.3%. Finally, we demonstrate improved repopulation of LNPFancc treated HSPC 2 weeks after intravenous delivery to myeloablated recipients, measuring up to 73.9% donor chimerism after treatment with circular LNPFancc compared to 50% among untreated (no LNP) controls.
Conclusion: Our studies show that LNPFancc can rescue Fancc-/- HSPC in vitro, and ongoing experiments reveal improved repopulation in vivo. Along with evidence for efficient in vivo delivery to the bone marrow, our data support the use of LNPmRNA as a potential in vivo treatment of bone marrow failure in FA patients.
Disclosures: Rivella: GSK: Consultancy, Ended employment in the past 24 months; Disc Medicine: Membership on an entity's Board of Directors or advisory committees; Vifor: Membership on an entity's Board of Directors or advisory committees; Meira GTx: Membership on an entity's Board of Directors or advisory committees; Ionis Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees; BMS: Consultancy, Ended employment in the past 24 months; Incyte: Consultancy, Ended employment in the past 24 months; Celgene Corporation: Consultancy, Ended employment in the past 24 months; Rallybio, LLC: Consultancy, Ended employment in the past 24 months.